Following intravenous injection of anti-cancer nanomedicines, many barriers need to be overcome en route to the tumor. Cell-mediated delivery of nanoparticles (NPs) is promising in terms of overcoming several of these barriers based on the tumoritropic migratory properties of particular cell types. This guided transport aims to enhance the NP accumulation in the tumor and moreover enhance the infiltration of regions that are typically inaccessible for free 
Introduction
Nanoparticles (NPs) have been widely investigated for the delivery of anti-cancer drugs to tumor tissues [1] [2] [3] . Although a lot of research has been performed, to date, only few nanomedicines are in clinical use for the treatment of cancer [4, 5] . One of the key challenges is inadequate targeted delivery of drug-loaded NPs to the tumor tissue following systemic administration. A critical barrier remains the vascular endothelium which controls the extravasation of NPs from the bloodstream into the target tissue [6, 7] . Because NP extravasation is dependent on the size of fenestrae, tumor tissue may favor this delivery route by its leaky blood vasculature. This increased extravasation in combination with the poor lymphatic drainage found in tumors results in the accumulation of NPs in the tumor tissue and is also known as the enhanced permeation and retention (EPR) phenomenon [8] .
Unfortunately, the widespread application of the EPR-based passive targeting of tumors is hampered by the heterogeneity in tumor vasculature both within a single tumor and between different tumor types [9] .
Besides relying on passive targeting alone, nanomedicines are frequently modified with a targeting ligand that specifically recognizes a receptor that is present on or overexpressed by tumor cells. Several studies have shown that this active targeting strategy enhances the internalization in the target cells, albeit without increasing the accumulation in the tumor tissue after systemic delivery [10] [11] [12] . Furthermore, it was observed that active targeting can hinder the diffusion of NPs into the tumor tissue due to the binding-site barrier phenomenon in which particles mainly bind to perivascular cells [1] .
One alternative strategy that might overcome these targeting limitations is cell-mediated delivery [13, 14] . Certain cell types have the intrinsic ability to cross the endothelial barrier and infiltrate the tumor tissue, which makes them attractive carriers for NP delivery [15] .
Moreover, tumors contain hypoxic and necrotic regions that are typically not easily accessible for NPs, leading to incomplete tumor regression [16, 17] . Monocytes and macrophages have already been investigated as carriers for the delivery of NPs in these low accessible regions [18] [19] [20] . Also T cells have the intrinsic ability to migrate to the tumor tissue. Moreover, cytotoxic CD8 + T lymphocytes (CTLs) have the added advantage of exerting a cytotoxic effect on tumor cells upon their recognition and binding of tumor-associated antigens. By virtue of these specific traits, the adoptive transfer of T cells is a widely investigated cancer
immunotherapy. Adoptive T cell therapy can be described as the transfer of ex vivo selected and expanded tumor-reactive T cells [21] . Although adoptive T cell therapy already showed impressive clinical outcomes, complete tumor regression was only observed in a restricted number of patients mainly due to the immunosuppressive tumor microenvironment and also the loss of tumor antigens to which the therapy was targeted [22, 23] . Therefore, strategies combining conventional chemotherapies with cancer immunotherapy have gained interest in recent years [24] .
The use of T cells as NP carrier cells has been assessed previously by Irvine and colleagues, who irreversible attached drug-loaded NPs to their surface and also by Vile and co-workers, who exploited T cells for the intratumoral delivery of therapeutic viral vectors [25] [26] [27] . Here, we propose a synergistic strategy based on CTLs that serve a dual purpose, i.e. induce a direct killing effect on tumor cells and enhance the delivery of drug-loaded NPs into tumor tissue, which may kill T cell-refractory tumor cells. To this end, we investigated the covalent attachment of NPs to the surface of CTLs. Moreover, we envisioned the triggered release of the cell surface-conjugated NPs in the tumor microenvironment which could allow their subsequent internalization by target tumor cells and hence a more efficient delivery of anticancer drugs. This concept is of particular interest for charged macromolecular therapeutics that are membrane-impermeable such as small interfering RNA (siRNA), which require NPmediated cytosolic delivery in target cells. To date, a reversible coupling strategy of NPs to the surface of CTLs has not yet been investigated.
Given their outstanding promise and versatility as drug delivery systems, we used liposomes as model nanomedicines within this proof-of-concept [28] . First, it was assessed whether liposomes can be attached to the surface of CTLs based on disulfide bond formation between exofacial thiols present on the CTL plasma membrane and thiol-reactive liposomes. Next, we
showed the triggered release of liposomes in the presence of glutathione as a reducing agent.
Importantly, in vitro data indicated that the NP-load did not affect the T cell functionalities such as proliferation and cytotoxic effector functions.
It has been demonstrated that the adoptive transfer of less differentiated T cells is associated with superior persistence and anti-tumor responses compared to the more differentiated effector T cells [29, 30] . On the other hand, the differentiation of naive T cells into CD8 + effector T cells is required for their migratory and cytotoxic function. Since both activated and naive T lymphocytes are investigated for adoptive T cell therapy, we therefore evaluated the reversible coupling of liposomes as a function of their activation status [31] .
Finally, building further on this optimized reversible coupling strategy, we demonstrated the coupling of lipid-enveloped nanogels, loaded with siRNA, to the surface of activated CD8 + T cells.
Materials and Methods

Preparation of liposomes and characterization:
The liposomes were composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), egg phosphatidylglycerol (egg PG) or 18:1 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3- 
Cell culture:
CD8 + T cells were isolated from the spleen of OT-I mice using a negative isolation CD8 + kit (stem cell technologies, Grenoble, France). Cells were activated with anti-CD3/CD28 Dynabeads ® (Gibco-Invitrogen) at a density of 2 x 10 6 cells/well and a bead-to-cell ratio of 1:1 in a 24-well plate. The cells were cultured in complete T cell culture medium containing advanced RPMI medium (Gibco-Invitrogen) supplemented with 10% fetal bovine serum (FBS; Hyclone, Thermo Scientific, MA, USA), 2 mM L-glutamine (Gibco-Invitrogen), 1%
penicillin/streptomycin (Gibco-Invitrogen). According to the manufacturer's protocol 30 U ml -1 rIL-2 (Miltenyi Biotec, Leiden, The Netherlands) was added to the culture medium and restimulation was performed by adding new beads every 7 days.
The mouse thymoma cell lines EL4 and E.G7-OVA were purchased from the American Type Culture Collection (ATCC). The E.G7-OVA cell line is an EL4 cell line that was stably transfected with the plasmid pAc-neo-OVA, which carries a complete copy of chicken ovalbumine (OVA) mRNA. Both cell lines were cultivated in RPMI 1640 (Gibco-Invitrogen)
supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin.
Visualization of exofacial thiol groups:
CD8 + T cells were incubated for 15 min with 100 µg ml -1 Cy5-labeled maleimide (GE Healthcare Life Sciences, Diegem, Belgium) at room temperature. After washing the cells with PBS, the cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, Bornem, Belgium). Confocal microscopy images were acquired using a Nikon C1si confocal laser scanning microscope (Nikon Benelux, Brussels, Belgium) equipped with a Plan Apo VC 60x
1.4 NA oil immersion objective lens (Nikon). The Cy5 dye was excited with a 636 nm diode laser (CVI Melles Griot, NM, USA). 
Characterization of detached liposomes by fluorescence single particle tracking (fSPT):
CD8 + T cells were first incubated with PDP-functionalized liposomes that were fluorescently labeled with DiD as described in the previous section, followed by two washing steps with PBS to remove the unbound particles. Subsequently, the cells were incubated with 2 mg ml The motion trajectories of single particles were obtained by in-house developed software.
Subsequently, the diffusion coefficient for each trajectory was calculated and transformed in a size distribution using the Stokes-Einstein equation. Data were further refined by the maximal entropy deconvolution method, as described by our group previously [32] .
Visualization of T cell surface-conjugated liposomes by confocal microscopy:
DiD-labeled liposomes were conjugated to the cell surface of CD8 + T cells as previously described, followed by a cell nucleus stain with 10 µg ml 
In vitro cytotoxic T cell (CTL) assay:
EL4 and E.G7-OVA cells were stained with 5 µM and 15 µM CFSE stain, respectively. The OT-I CTLs were activated for 9 days with anti-CD3/CD28 Dynabeads ® and incubated with PDP-functionalized liposomes at a concentration of 5 mg ml -1 lipids, followed by two washing steps to remove unbound particles. Subsequently, the OT-I T cells were co-cultured with EL4 and E.G7-OVA cells at two different effector-to-target ratios. To increase cell contact between T cells and target cells, the incubation was performed in a U-bottom 96-well plate (Falcon, BD Biosciences) in complete T cell culture medium. After 4h at 37 °C the ratio of EL4 cells compared to E.G7-OVA cells was quantified by flow cytometry, in which the viable population was selected based on forward scatter/side scatter and both cell lines could be distinguished by their different CFSE fluorescence intensity signal.
Coupling of siRNA-loaded nanoparticles to CD8 + T cells:
Our group has developed biodegradable dextran nanogels (NGs) via an inverse mini-emulsion photopolymerization of dextran hydroxyethyl methacrylate (dex-HEMA) in mineral oil. To incorporate cationic charges in the nanoscopic hydrogel network, cationic methacrylate monomers ([2-(methacryloyloxy)-ethyl]trimethylammonium chloride, TMAEMA, SigmaAldrich) were copolymerized with dex-HEMA [33] . Recently, experimental evidence was provided that these siRNA-loaded NGs (siNGs) can efficiently be coated with a lipid bilayer [34] . Here, the NGs were first loaded with 5 pmol AlexaFluor488-labeled siRNA Upon encapsulation in NPs, the fluorescence baseline of the siRNA molecules will drop, from which the loading efficiency can be calculated as described earlier.
As was shown by our group, the complexation of siRNA molecules in NPs can be determined in different media including full human serum [35] . Within this study, the siRNA release from the non-coated versus lipid-coated siNGs was measured in the presence of competing polyanions such as dextran sulfate (DEXS; 10kDa; 2.5 mg ml 
Statistical analysis:
A two-tailed Student's t-test was performed to determine statistical differences between datasets. All statistical analyses were performed using GraphPad Prism 6 software (La Jolla, CA, USA). p-values <0.05 were regarded significant. Statistical significance is indicated as follows: **p <0.01; ***p < 0.001; ****p < 0.0001.
Results
Liposomes for reversible attachment to cytotoxic T lymphocytes
Within this study liposomes were selected as model nanoparticles (NPs) to optimize reversible coupling to cytotoxic T lymphocytes (CTLs). Varying amounts of thiol-reactive phospholipids, carrying a pyridyldithiopropionate (PDP) head group, were incorporated in the liposome bilayer, next to DOPC lipids. The PDP moiety can form a reducible disulfide bond with the thiol groups exposed at the cell surface (exofacial thiols), allowing the reversible covalent coupling of the liposomes ( Figure 1A ) [36] . Importantly, PDP-functionalized lipids (PE-PDP lipids) contain a negative charge that may interact with cationic regions at the plasma membrane, thereby possibly causing nonspecific binding [37] . To account for these nonspecific interactions, the cellular attachment of control liposomes, in which the PDP- 
Reversible coupling of liposomes to the surface of non-activated CD8 + T cells
Murine OT-I CD8 + T cells, which are genetically engineered to express a T cell receptor (TCR) against ovalbumine (OVA), were selected as carriers for the cell-mediated delivery of the liposomes. To allow the formation of a disulfide bond between free thiol groups at the CTL plasma membrane and PDP liposomes, we first assessed the availability of free thiol groups at the CD8 + T cell surface by incubating them with Cy5-labeled maleimide [36] . The maleimide group can interact with thiol groups to form a stable thioether bond. Confocal images clearly demonstrated the presence of thiol groups that appeared to be uniformly distributed over the entire cell surface ( Figure 1B) .
Attachment of liposomes to the surface of non-activated CD8 + T cells
Isolated CD8 + T cells from the spleen of OT-I mice were incubated with fluorescently labeled (DiD) liposomes and the amount of liposomes coupled to the cell surface was quantified by flow cytometry. We first determined the fraction of PDP lipids that needs to be incorporated into the liposomal membrane to achieve efficient binding. To this end, the cells were incubated with liposomes containing increasing amounts of PDP lipids, ranging from 10 to 50 wt%. Cells were incubated with a 2 mg ml -1 lipid concentration as we determined that a higher concentration only results in a moderate increase in cellular attachment ( Figure S1 ).
To quantify nonspecific interactions, the cellular binding of PG liposomes with PG lipid wt% also ranging from 10 to 50, was determined in parallel. It was verified that both PDP and PG liposomes have equivalent zeta potentials ( Figure 2A) . As displayed in Figure 2B The presence of fluorescently labeled liposomes at the surface of the CD8 + T cells was visualized by confocal microscopy. The images depicted in Figure 2C show localized bright fluorescent spots at the T cell surface, contrary to the free thiol staining with Cy5-labeled maleimide that showed a more uniform distribution ( Figure 1B) . Of note, from these images it is evident that the liposomes are indeed predominantly anchored to the surface of the cells and not internalized, confirming previous reports [25, 38] . represent MFI ± SD (n = 3; ns = not significant; *** = p<0.001; **** = p<0.0001).
Triggered detachment of liposomes from the cell surface of non-activated CD8 + T cells.
Having established the optimal liposome composition, we next sought to evaluate whether the liposomes can be detached again from the cell surface. We anticipated that incubating the liposome-loaded T cells with reducing agents such as glutathione can cause a thiol-disulfide exchange reaction, resulting in the release of the disulfide-bound liposomes from the T cell surface [39] . To explore the latter, the liposome-loaded CD8 + T cells were incubated with mounting concentrations of glutathione. As depicted in Figure 2D , an increase in the glutathione concentration was associated with a decrease in the amount of attached DiDlabeled PDP liposomes, indicative of their triggered release. Upon incubation with 2 mg ml
glutathione, a release of 60% of the attached particles was observed.
Reversible coupling of liposomes to the surface of activated CD8 + T cells
Given that activated T cells outperform their non-activated counterparts in terms of tumor migratory capacity and cytolytic activity, we next aimed to assess the impact of T cell activation on the covalent coupling of liposomes. For this purpose, murine OT-I T cells were activated using anti-CD3/CD28 Dynabeads ® . The activation status was evaluated by the expression of the IL-2 receptor CD25, which is up-regulated after stimulation [40] .
Attachment of liposomes to the surface of activated CD8 + T cells
Similar to the attachment of liposomes to the surface of non-activated T cells, the coupling of liposomes to activated CD8 + T cells was first quantified as a function of wt% incorporated PDP lipids. The zeta potential data from the different liposome compositions were represented in Figure 3A . In accordance with the results on non-activated CD8 + T cells, we again observed a significant specific binding only for the liposomes with 50 wt% PE-PDP lipids incorporated ( Figure 3B) . Thus, also for the activated T cells this composition was selected for further investigation. To evaluate the maximal coupling, the cells were incubated with increasing liposome concentrations. A sharp increase in cell binding was observed from 0.1 to 1 mg ml -1 lipids while a further increase up to 10 mg ml -1 only resulted in a moderate improvement of the coupling (Figure 3C ). In analogy with non-activated T cells, liposomes bound to activated T cells also remain localized at the cell surface in distinct foci, as verified with confocal microscopy ( Figure 3D) . 
intensity (MFI) per cell ± SD (n = 3). (D) Confocal images of T cells incubated with
AlexaFluor488-labeled anti-CD8 antibodies (green), Hoechst cell nucleus stain (blue), and DiD-labeled liposomes (red) (Scale bar = 5 µm).
Attachment of liposomes as a function of T cell activation status
During the activation process CD8 + T cells undergo phenotypic changes such as up-regulation of multiple surface markers like CD25, as represented in Figure 4A , and a marked increase in size ( Figure S2 ). To address whether these changes influence the attachment of particles to the cell surface, CD8 + T cells were activated with anti-CD3/CD28 Dynabeads ® over a twoweek time period and the specific coupling of liposomes was quantified at different activation time points (Figure 4A ). In accordance with the manufacturer's protocol, the cells were restimulated with new Dynabeads ® on day 7 of activation.
In general, a significantly higher attachment of PDP-functionalized liposomes to activated cells was observed compared to the non-activated T cells. In analogy with previous experiments, PG liposomes were incubated with the T cells as a control for nonspecific binding. Here, a similar trend in T cell binding was detected, albeit with markedly lower fluorescence intensity. Furthermore, the expression of the CD25 surface marker strongly increased from day 7 to day 10 following activation, indicative of an improved T cell activation efficiency upon a second activation step with anti-CD3/CD28 Dynabeads ® on day 7. In contrast, when exceeding 10 days of activation again a gradual decrease in CD25 expression was observed. Importantly, the efficiency of liposome coupling to the T cells perfectly correlates with the CD25 expression levels, also reaching optimal specific liposome attachment to the T cell surface at day 10 of activation. 
Triggered detachment of liposomes from the cell surface of activated CD8 + T cells
To verify that the coupling of PDP liposomes to the surface of activated T cells was indeed reversible, the release of liposomes from the surface was evaluated by incubating the activated and liposome-loaded CD8 + T cells with glutathione. In accordance with the data obtained from non-activated T cells, the glutathione concentration was fixed at 2 mg ml -1 .
Glutathione was able to release ~50% of the PDP liposomes from the CD8 + T cells surface, The liposomes that were released from the T cell surface in the presence of glutathione have a slightly increased average diameter (228 nm), which remains within an acceptable size range for subsequent endocytosis by tumor cells (Figure 4C ).
Influence of cell surface-attached liposomes on T cell functionalities
Proliferation of CD8 + T cells after coupling of liposomes
Proliferation is one of the key cellular functions of T cells upon activation. We therefore 
Cytotoxic T cell effector function after coupling of liposomes
CTLs are designed to specifically kill target tumor cells. To evaluate whether the anchoring of liposomes to the surface of CD8 + T lymphocytes affects their cytotoxic function, OT-I T lymphocytes were used that have a TCR recognizing an ovalbumine (OVA)-derived peptide.
Co-culturing of OT-I T cells with E.G7-OVA lymphoma cells that present this OVA-peptide in MHC class I, would result in TCR-mediated killing of the E.G7-OVA cells. Isogenic yet OVA negative EL4 cells were included in the co-culture experiment as a control for the specificity of this interaction. To discriminate both cell types, EL4 and E.G7-OVA cells, were stained with a low and high concentration of CFSE, respectively. The CFSE-labeled EL4 and E.G7-OVA cells were mixed in equal amounts followed by the addition of the OT-I T cells in an effector:target (E:T) ratio of 1:1 and 1:20 as indicated in Figure 6 . A schematic of this experiment is represented in supplementary Figure S4 .
At a 1:1 effector:target ratio the OT-I T cells were able to lyse the majority of the E.G7-OVA population in contrast to the EL4 cells that remained unaffected, reflecting the specificity of the CTL effector function assay. Notably, Figure 6B clearly demonstrates that the covalent attachment of liposomes to the T cell surface does not interfere with their cytotoxic function as both liposome-loaded and non-loaded T cells killed 72% of the E.G7-OVA population. To exclude the possibility that this E:T ratio was too high and could therefore obscure the inhibitory effect of the conjugated liposomes, the co-culture experiment was repeated at a suboptimal E:T ratio of 1:20. Although the killing effect of the E.G7-OVA cells obtained at the 1:20 ratio is strongly reduced with only 6% lysis compared to 72% for the 1:1 ratio, again the attachment of liposomes to the T cell surface did not affect target cell lysis ( Figure 6C ).
Quantitative data of this CTL assay are represented in Figure S5 . Cells were mixed in both a (B) 1:1 effector:target (E:T) ratio and a (C) 1:20 E:T ratio.
Coupling of siRNA-loaded nanoparticles to CD8 + T cells
Next, a drug-loaded nanoparticle was developed for anchoring to the surface of CD8 + T cells, exploiting our previously optimized coupling protocol. As a therapeutic agent we selected small interfering RNA (siRNA), which needs to be delivered into the cytosol of target cells to activate gene silencing. However, as the PDP-liposomes are negatively charged they do not allow loading of siRNA based on electrostatic interaction. To this end, our research group recently developed a hybrid core-shell formulation, in which siRNA is pre-loaded in a biodegradable cationic nanogel (NG) core that is subsequently coated with a negatively charged lipid shell [34] . Here, we modified this nanocomposite formulation using PDPliposomes to construct the outer lipid shell and to enable subsequent coupling of the siRNAloaded nanogels (siNGs) to the CD8 + T cell surface.
Following incubation of this core-shell formulation with activated CD8 + T cells, we could demonstrate their coupling to the T cell surface. In Figure 7A , confocal images show the coupling of double-labeled PDP lipid-coated siNGs to CD8 + T cells, in which the greenlabeled siRNA (AlexaFluor488) perfectly co-localizes with the red-labeled (DiD) lipid coat.
In addition, flow cytometry plots indicated that all T cells were loaded with the lipid-coated siNGs as the fluorescent signals of both labeled siRNA and lipids are closely correlated ( Figure 7B) . During the coating procedure of the siNGs with the highly anionic PDPliposomes a small fraction (~10%) of siRNA was released from the NG core. Importantly, Figure 7C shows that the lipid coat offers ample protection against siRNA decomplexation in the presence of high concentrations of competing polyanions and in human serum, which indicates the successful deposition of a protective lipid shell around the siNG core. 
Discussion
The primary goal of this study was to investigate whether liposomes can be reversibly attached to the surface of cytotoxic T cells (CTLs). To this end, we exploited the presence of thiol groups naturally present on the surface of cells (exofacial thiols) to covalently couple liposomes that are equipped with thiol-reactive PDP groups through the formation of a disulfide bond. Our results clearly demonstrate that the surface of the T cells can be conjugated with high amounts of liposomes. Although the exofacial thiol groups appear to be uniformly distributed over the plasma membrane, as evaluated with Cy5-maleimide, confocal microscopy imaging revealed a more speckled distribution profile for the liposomes which is in agreement with previous observations by Irvine and colleagues [38] . It is conceivable that only a fraction of the exposed thiols at the cell surface is accessible for thiol-reactive nanoparticles (NPs) in contrast to small molecules which are less prone to steric hindrance.
Another important observation is the need to incorporate a substantial fraction (50 wt%) of thiol-reactive lipids in the liposomal formulation to achieve a significant and specific cell surface binding, both for activated and non-activated T cells. We hypothesize that the presence of high amounts of thiol-reactive lipids could anchor a single liposome to the T cell surface via multiple disulfide bonds, thereby rendering the coupled liposomes more resistant to the various washing steps and disulfide cleavage possibly occurring at the cell surface by thioredoxins and oxidoreductases that initiate thiol-disulfide exchanges [41, 42] . Our study also revealed the importance of the activation status of the T cells toward liposomal coupling.
We could demonstrate a five-fold increase in the attachment of liposomes for T cells activated Within this study, the reducing agent glutathione was selected as a tumor-specific trigger for subsequent liposome detachment from the T cell surface. Indeed, glutathione levels are low in the circulation and extracellular fluids while elevated levels can be found inside cells, thus avoiding premature liposome release [44] . On the other hand, the tumor microenvironment typically shows increased thiolytic activity, originating from the release of glutathione by dead cells and the overexpression of thiolytic proteins such as thioredoxin, enabling the uncoupling of disulfide-linked NPs in the direct vicinity of tumor cells [45] . In the presence of glutathione, 50-60% detachment was achieved in both activated and non-activated T cells.
The inability to achieve complete release of the coupled liposomes is likely due to both nonspecific interactions and the requirement that multiple disulfide bonds need to be broken up simultaneously. As represented in Figure S4 , the confocal images show that the partial detachment is not due to internalization of the particles, as it can be observed that the refractory particles are still located at the surface of the T cells. In addition, previous reports on the internalization of particles in T cells agree that the endocytic uptake of NPs in this cell type is rather exceptional. Nevertheless, we could show that the liposomes do not tend to aggregate upon release from the cell surface as only a minor increase in the liposome diameter was observed compared to the original liposomes. The latter is of key importance for the subsequent internalization of the released particles in the target tumor cells.
In general, the use of cells as carriers was inspired by the observation that certain pathogens can evade the immune system by attaching themselves to the surface of red blood cells [46] [47] [48] . These observations paved the way for NP cell-mediated delivery, in which the carriers might prevent the clearance of the particles upon intravenous injection and enhance the accumulation of NPs in inaccessible regions [49] [50] [51] . Different coupling strategies have been assessed such as passive adsorption and ligand-receptor interactions, however, the covalent linkage of particles to reactive groups that are present at the cellular surface has proven most promising in terms of coupling stability [13, 52] .
To our knowledge, this is the first study that demonstrates the reversible coupling of NPs to
CTLs. This reversible strategy is of interest to improve the intratumoral delivery of both low molecular weight chemotherapeutic drugs but is of particular interest for membrane- Although the injection of tumor-specific T cells as a therapy already showed impressive clinical outcomes, the limited number of patients that can be cured with this therapy is often related to the immunosuppressive role of the tumor microenvironment, the intra-tumor heterogeneity, and loss of antigens to which the adoptive T cell therapy was engineered [55, 56] .
These factors jointly underscore the need to investigate combinatorial anti-cancer strategies leading to synergistic effects as was suggested here via the enhancement of the efficacy of the T cell therapy by the concurrent delivery of siRNA-loaded NPs, acting against adoptive T cell therapy-refractory tumor cells and/or immunosuppressive cells. Future research will be focused on the in vivo evaluation of this novel concept in validated models of adoptive T cell therapy.
Conclusion
A novel technique was developed to reversibly attach lipid-based NPs to the surface of CTLs.
This study revealed the importance of both the lipid composition and the cell activation status on the loading efficiency of the CD8 + T cells. Furthermore, it was shown that the presence of 
